Приказ основних података о документу
Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities
dc.creator | Vukotić, Milica | |
dc.creator | Kapor, Sunčica | |
dc.creator | Simon, Felipe | |
dc.creator | Čokić, Vladan | |
dc.creator | Santibanez, Juan F. | |
dc.date.accessioned | 2024-02-13T13:36:18Z | |
dc.date.available | 2024-02-13T13:36:18Z | |
dc.date.issued | 2024 | |
dc.identifier.issn | 2405-8440 | |
dc.identifier.uri | http://rimi.imi.bg.ac.rs/handle/123456789/1458 | |
dc.description.abstract | Myeloid malignancies are clonal disorders of the progenitor cells or hematopoietic stem cells, including acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative malignancies, and chronic myelomonocytic leukemia. Myeloid neoplastic cells affect the proliferation and dif- ferentiation of other hematopoietic lineages in the bone marrow and peripheral blood, leading to severe and life-threatening complications. Mesenchymal stromal cells (MSCs) residing in the bone marrow exert immunosuppressive functions by suppressing innate and adaptive immune systems, thus creating a supportive and tolerant microenvironment for myeloid malignancy progression. This review summarizes the significant features of MSCs in myeloid malignancies, including their role in regulating cell growth, cell death, and antineoplastic resistance, in addition to their immunosuppressive contributions. Understanding the implications of MSCs in myeloid malig- nancies could pave the path for potential use in immunotherapy. | |
dc.publisher | Elsevier | |
dc.relation | info:eu-repo/grantAgreement/MESTD/inst-2020/200015/RS// | |
dc.relation | FONDECYT Grant 1201039 (FS) | |
dc.relation | ONDECYT Grant 1201039 (FS), National Research and Development Agency (ANID) - Millennium Science Initiative Program - ICN09_016/ICN 2021_045: Millennium Institute on Immunology and Immunotherapy (ICN09_016/ICN 2021_045; former P09/016-F) (FS). | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | Heliyon | |
dc.subject | Myeloid malignancies | |
dc.subject | Myeloid cells | |
dc.subject | Mesenchymal stromal cells | |
dc.subject | Cell differentiation | |
dc.subject | T-cell immunosuppression therapy | |
dc.title | Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities | |
dc.type | article | |
dc.rights.license | BY | |
dc.citation.issue | 3 | |
dc.citation.spage | e25081 | |
dc.citation.volume | 10 | |
dc.identifier.doi | 10.1016/j.heliyon.2024.e25081 | |
dc.identifier.fulltext | http://rimi.imi.bg.ac.rs/bitstream/id/3438/Mesenchymal_stromal_cells_in_myeloid_pub_2024.pdf | |
dc.type.version | publishedVersion |